Lupin launches first generic version of Oracea in United States

10 Apr 2024 Evaluate

Lupin has launched first generic version of Oracea (Doxycycline Capsules, 40 mg), in the United States, after having received an approval from the United States Food and Drug Administration (USFDA). Doxycycline Capsules, 40 mg is indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. Doxycycline Capsules had estimated annual sales of $128 million in the U.S. (IQVIA MAT February 2024).

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.


Lupin Share Price

2123.90 -23.70 (-1.10%)
28-Jan-2026 13:49 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1609.45
Dr. Reddys Lab 1223.35
Cipla 1318.50
Zydus Lifesciences 889.10
Lupin 2123.90
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×